Recent Advances in Melanoma Staging and Therapy

[1]  G. Lyman,et al.  Molecular staging of malignant melanoma: correlation with clinical outcome. , 1998, JAMA.

[2]  F. Haluska.  Adjuvant interferon for stage II melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Dummer,et al.  Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Steinberg,et al.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.

[5]  M. Ross,et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Kirkwood,et al.  Adjuvant therapy of melanoma. , 1998, Seminars in surgical oncology.

[7]  M. Binder,et al.  Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Cascinelli,et al.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial , 1998, The Lancet.

[9]  S. Calvieri,et al.  Postsurgical adjuvant therapy for melanoma , 1997, Cancer.

[10]  C. Chastang,et al.  Long term results of an adjuvant therapy with low doses IFN-??2A in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases: 113 , 1997 .

[11]  M. Kashani-Sabet,et al.  Optimal selective sentinel lymph node dissection in primary malignant melanoma. , 1997, Archives of surgery.

[12]  M. Ross,et al.  Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  V. Sondak,et al.  Adjuvant therapy for melanoma. , 1997, Current opinion in oncology.

[14]  M. Lotze,et al.  Dendritic Cell Based Therapy of Cancer , 1997 .

[15]  Messina,et al.  Lymphatic Mapping for Melanoma: Long-term Results of Regional Nodal Sampling With Radioguided Surgery. , 1997, Cancer control : journal of the Moffitt Cancer Center.

[16]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Mihm,et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. , 1996, Annals of surgery.

[18]  D. Reintgen,et al.  The Use of Intraoperative Radiolymphoscintigraphy for Sentinel Node Biopsy in Patients with Malignant Melanoma , 1996, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[19]  D. Colomer,et al.  Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Eshima,et al.  Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. , 1996, Radiology.

[21]  P. Lam.  Minimal-access surgery for staging of malignant melanoma , 1996 .

[22]  G. Lyman,et al.  The tumor biology of melanoma nodal metastases. , 1996, The American surgeon.

[23]  C W Cruse,et al.  Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. , 1996, Annals of surgery.

[24]  J. Kugler,et al.  Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  N. Bleehen,et al.  Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Reintgen,et al.  Detection of Submicroscopic Lymph Node Metastases with Polymerase Chain Reaction in Patients with Malignant Melanoma , 1994, Annals of surgery.

[27]  M. Ross,et al.  The Orderly Progression of Melanoma Nodal Metastases , 1994, Annals of surgery.

[28]  M. Cuesta,et al.  Gamma probe‐guided sentinel node biopsy to select patients with melanoma for lymphadenectomy , 1994, The British journal of surgery.

[29]  A. Cochran,et al.  Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Ross,et al.  Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. , 1993, Seminars in surgical oncology.

[31]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[32]  N. Cascinelli,et al.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities , 1982, Cancer.

[33]  F. Sim,et al.  A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results , 1978, Cancer.

[34]  D. Morton,et al.  Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.